Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some safety claims (seizures, orthostatic hypotension, myocarditis/cardiomyopathy, agranulocytosis/neutropenia, and need for blood/ANC monitoring) align with provided label sections, but several statements are not supported or are inaccurate/inconsistent with the supplied label excerpts (e.g., suicide-risk reduction indication, “not fully understood” mechanism, agranulocytosis phrasing, trade names list). Major dosing/administration details are not assessed because the response provides no label dosing guidance.
Category Scores
Accurate Statements
Clozapine can cause orthostatic hypotension.
Supported by Warnings and Precautions (5.2 Orthostatic hypotension, bradycardia, syncope, and cardiac arrest).
Clozapine can cause seizures.
Supported by Warnings and Precautions (5.4 Seizures).
Clozapine can cause myocarditis.
Supported by Warnings and Precautions (5.5 Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence).
Clozapine can cause cardiomyopathy.
Supported by Warnings and Precautions (5.5 Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence).
Patients taking clozapine must have their blood monitored regularly due to the risk of agranulocytosis.
Supported by Warnings and Precautions (5.1 Severe Neutropenia) requiring baseline ANC(s) and ANC-based monitoring recommendations (referenced in 5.1).
Unsupported Statements
Other trade names for clozapine include Alepcin.
Not supported by the supplied label excerpts.
Other trade names for clozapine include Azaleptin.
Not supported by the supplied label excerpts.
Other trade names for clozapine include Clozapine Varian.
Not supported by the supplied label excerpts.
Other trade names for clozapine include FazaCllo.
Not supported by the supplied label excerpts.
Other trade names for clozapine include Leponex.
Not supported by the supplied label excerpts.
Clozapine is used to reduce the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder.
Not supported by the supplied Indications and Usage excerpt (1.1 Treatment-Resistant Schizophrenia).
The exact mechanism of action for clozapine is not fully understood.
Not supported by the supplied label excerpts.
Clozapine is believed to affect dopamine and serotonin receptors in the brain.
Not supported by the supplied label excerpts.
Clozapine was first approved by the U.S. Food and Drug Administration (FDA) in 1989.
Not supported by the supplied label excerpts.
Clozapine is generally reserved for treatment-resistant cases due to its risk profile.
While consistent with the general concept in the supplied Indications/Usage (used only in patients who fail standard antipsychotic treatment), the response frames this as a broader risk-profile rationale not explicitly stated in the excerpted wording. Partially aligned but not fully supported as written.
The original patents for clozapine have long expired.
Not supported by the supplied label excerpts.
Other medications used to treat schizophrenia include aripiprazole (Abilify).
Not supported by the supplied label excerpts for clozapine.
Other medications used to treat schizophrenia include olanzapine (Zyprexa).
Not supported by the supplied label excerpts for clozapine.
Other medications used to treat schizophrenia include quetiapine (Seroquel).
Not supported by the supplied label excerpts for clozapine.
Other medications used to treat schizophrenia include risperidone (Risperdal).
Not supported by the supplied label excerpts for clozapine.
Clozapine is an older medication.
Not supported by the supplied label excerpts.
Clozapine is available as an oral tablet.
Not supported by the supplied label excerpts (which specify oral suspension for VERSACLOZ and oral tablets for CLOZARIL only in the user-provided context, not in FDA label text excerpts).
Clozapine is available as an orally disintegrating tablet.
Not supported by the supplied label excerpts.
Clozapine can cause agranulocytosis.
The supplied label excerpt uses the term 'severe neutropenia' (5.1) rather than 'agranulocytosis'; support is indirect and phrasing is not directly supported by the excerpted label text.
Contradictions
Important Omissions
Dosing initiation and titration details recommended to minimize orthostatic hypotension/bradycardia/syncope (e.g., starting at 12.5 mg once or twice daily and slow titration) were not provided.
Importance:
Moderate
Baseline ANC requirement and initiation not recommended thresholds (e.g., baseline ANC <1500/µL not recommended) were not specified.
Importance:
Moderate
Boxed warning regarding increased mortality in elderly patients with dementia-related psychosis was not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant effects align with label topics (neutropenia requiring ANC monitoring, orthostatic hypotension, seizures, myocarditis/cardiomyopathy), but key label specifics (ANC thresholds/requirements, boxed warning population restriction, and orthostatic risk-minimizing dosing guidance) are omitted. Additionally, the purported indication for reducing suicidal behavior is not supported by the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Indication claim for reducing suicidal behavior and several unsupported details (mechanism/patents/trade names/other formulations) are not supported by the supplied label excerpts; several key boxed-warning and ANC/dosing thresholds are omitted.
Suggested Improvement
Limit claims to the provided label-supported indications and warnings; remove or qualify unsupported mechanism/trade-name/date/formulation statements; include boxed warning context and ANC-based monitoring/threshold language; add label-consistent dosing/titration details for orthostatic hypotension/bradycardia/syncope risk reduction.